AJMC Staff

High-risk patients with diffuse large B-cell lymphoma (DLBCL) may benefit from being treated with a regimen that adds zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody rituximab plus the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone).

An overview of the latest news in Parkinson disease (PD) reported across MJH Life Sciences™.

The latest phase 2 MAGNOLIA results continue to show strong efficacy and tolerability for the Bruton tyrosine kinase inhibitor in marginal zone lymphoma.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The pandemic led to decreased rates of routine childhood vaccinations; changes could inhibit use of pre-exposure prophylaxis (PrEP); officials extend the shelf-life of the Johnson & Johnson (J&J) COVID-19 vaccine.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

United States to buy and donate 500 million COVID-19 vaccine doses to the world; an FDA advisor resigns over a controversial Alzheimer drug approval; Nevada becomes the second state to offer state-managed health insurance plans.

A study out of Israel shows Pfizer’s COVID-19 vaccine is highly effective in patients with cancer; women with alcohol disorders face adverse health consequences sooner; hundreds of thousands of doses of Johnson & Johnson’s COVID-19 vaccine may expire in June.

FDA and ASPR issue policy recommendations to reform US pharmaceutical supply chains; insurer coverage implications of the newly approved therapy in Alzheimer disease; Apple announces new health data sharing features.

The FDA approves a new drug for Alzheimer disease; COVID-19–related hospitalization rates are on the rise among adolescents; efforts to address racism, discrimination, and implicit bias in health care; the United States will send 1 million Johnson & Johnson COVID-19 vaccines to Mexico cities along the border and resorts.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Eighteen months into the pandemic, states continue to report flawed racial and ethnic data on vaccine administration; promising study results have been seen for a breast cancer pill; 2 billion COVID-19 vaccines have been administered worldwide.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

If 2020 was dominated by the news of how COVID-19 spread across the globe, then 2021 has so far been focused on ending the pandemic through vaccine distribution.

President Joe Biden announces a new initiative to get more adults vaccinated against COVID-19; Purdue Pharma may be immune from future opioid-related lawsuits; the California senate approves a bill decriminalizing psychedelic drugs.

The FDA releases label changes for ozanimod to treat multiple sclerosis; the National Institute of Allergy and Infectious Diseases initiated a study on mixing COVID-19 vaccines; gender-affirming hormones may affect the cardiovascular system.

The World Health Organization simplifies the names of COVID-19 variants; updated Equal Employment Opportunity Commission guidance suggests employers can mandate COVID-19 vaccines; study finds a record 1.1 billion smokers were reported worldwide in 2019.

New studies evaluate the impact of age on overall survival in adolescents and young adults (AYAs) with chronic lymphocytic leukemia, as well as response rates of rituximab in 2 combination regimens for hairy-cell leukemia and follicular lymphoma.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

FDA panel members acknowledged the challenges and significant unmet need that patients with T1D face, along with the small size of the pivotal study.

An overview of the latest news in Parkinson disease reported across MJH Life Sciences™.

A CDC report finds that the risk of COVID-19 infection among those fully vaccinated is 0.01%; HHS announce it is designating $4.8 billion to cover COVID-19 testing for uninsured US residents; European Union seeks significant fine for AstraZeneca over breach of vaccine supply contract.

Recent coverage from Targeted Oncology® highlights how combination therapies are impacting the treatment spectrum for chronic lymphocytic leukemia (CLL).

Optogenics was used to partially restore a blind man’s eyesight; the FDA could soon approve Moderna’s COVID-19 vaccine for use among adolescents; HHS calls for a new investigation into COVID-19’s origins.

The CDC is looking into rare reports of myocarditis in teens who received a COVID-19 vaccine; reduced air pollution during lockdowns prevented premature deaths; new COVID-19 cases in the United States fall to a 1-year low.

Birth control guidance provided to women taking rheumatoid arthritis therapies is lacking, and other rheumatology news reported across MJH Life Sciences™.

Generalized pustular psoriasis (GPP) may have therapies in a few years; how patients define remission in psoriatic arthritis (PsA).